TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30896447

Group type: EXPERIMENTAL
Intervention: CART-BCMA cells alone (1-5 x 10^8 cells)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 1.5 g/m2 + CART-BCMA cells (1-5 x 10^7 cells)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 1.5 g/m2 + CART-BCMA cells (1-5 x 10^8 cells)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CART-BCMA infusions with or without lymphodepleting chemotherapy
Number of subjects: 25
Study: 30896569

Group type: EXPERIMENTAL
Intervention: Shark mouth pancreaticojejunostomy
Number of subjects: 120
Study: 30896610

Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI) with identification of 'Purple in Mist' (PIM) in the surface layer, followed by targeted biopsies.
Number of subjects: 63
Study: 30896746

Group type: EXPERIMENTAL
Intervention: Energy deficiency and estrogen deficiency
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Energy deficiency
Number of subjects: 109

Group type: COMPARATOR
Intervention: Estrogen deficiency but energy replete
Number of subjects: 109
Study: 30896779

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 30897531

Group type: EXPERIMENTAL
Intervention: Fibrinogen and fibrinogen γ'
Number of subjects: 182

Group type: COMPARATOR
Intervention: VWF:Ag or ADAMTS13 levels
Number of subjects: 182
Study: 30897573

Group type: EXPERIMENTAL
Intervention: Amnioinfusions to treat early pregnancy renal anhydramnios (EPRA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated EPRA
Number of subjects: 0
Study: 30898093

Group type: EXPERIMENTAL
Intervention: TANITA scale
Number of subjects: 38

Group type: COMPARATOR
Intervention: BIA-BIACORPUS
Number of subjects: 38
Study: 30898133

Group type: EXPERIMENTAL
Intervention: Implementation strategies identified and defined by the ERIC taxonomy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly proposed ERIC strategies.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional groupings of ERIC implementation strategies.
Number of subjects: 0
Study: 30898164

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 335
Study: 30898232

Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB2) intervention for pulmonary vein isolation (PVI)
Number of subjects: 344
Study: 30898249

Group type: EXPERIMENTAL
Intervention: Eruptive calcified nodules
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Superficial calcific sheet
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Calcified protrusion
Number of subjects: 1241
Study: 30898607

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day
Number of subjects: 8179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8179
Study: 30898821

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg daily oral treatment, initiated before conception and stopped at 10 weeks' gestation.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo, daily oral treatment, initiated before conception and stopped at 10 weeks' gestation.
Number of subjects: 300
Study: 30898849

Group type: EXPERIMENTAL
Intervention: External loop recording (ELR)
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Continuous ECG
Number of subjects: 1412
Study: 30899211

Group type: EXPERIMENTAL
Intervention: EEG-BCI-FES device intervention (maximum of 18-30 hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 30899278

Group type: EXPERIMENTAL
Intervention: C1-INH(SC) 60 IU/kg twice weekly (n=45)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: C1-INH(IV) 1000 U twice weekly (n=22)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 30899297

Group type: EXPERIMENTAL
Intervention: Presence of spider nevus
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Presence of subcutaneous collateral vessel of the chest/abdominal wall
Number of subjects: 198
Study: 30899469

Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide and bromocriptine
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide
Number of subjects: 1
Study: 30899835

Group type: EXPERIMENTAL
Intervention: DSJI (disposable-syringe jet injector)
Number of subjects: 128

Group type: COMPARATOR
Intervention: N-S (needle-syringe)
Number of subjects: 128
Study: 30900412

Group type: EXPERIMENTAL
Intervention: Prepregnancy BMI
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Gestational weight gain
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Postpartum weight loss
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oral glucose challenge test results
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Time interaction for insulin
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Time interaction for adiponectin
Number of subjects: 135
Study: 30900994

Group type: EXPERIMENTAL
Intervention: Point-of-care STI screening every 4 months for 24 months, including rapid HIV, syphilis, Chlamydia trachomatis, Neisseria gonorrhoeae, and Hepatitis C virus testing.
Number of subjects: 1720
Study: 30901746

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 260

Group type: COMPARATOR
Intervention: Microscopic surgery
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 260
Study: 30901867

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Combination of 4 mg ondansetron and 4 mg dexamethasone
Number of subjects: 1287

Group type: COMPARATOR
Intervention: Control arm (placebo)
Number of subjects: 1287
Study: 30901876

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Number of subjects: 32
Study: 30902090

Group type: EXPERIMENTAL
Intervention: Centiloid cut-off of 12 CL
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Centiloid cut-off of 30 CL
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Centiloid cut-offs in the range of 25-35
Number of subjects: 516
Study: 30902361

Group type: EXPERIMENTAL
Intervention: Intranasal hydromorphone (0.03 mg/kg initial dose, additional 0.015 mg/kg if needed)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intranasal hydromorphone
Number of subjects: 35
Study: 30902630

Group type: EXPERIMENTAL
Intervention: BCI-FES
Number of subjects: 1
Study: 30902689

Group type: EXPERIMENTAL
Intervention: Text message (TM) alert system and bystander CPR (part of a bundle intervention)
Number of subjects: 3194
Study: 30902907

Group type: EXPERIMENTAL
Intervention: Motor Function Measure 32 total score
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Grip and pinch strengths
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Forced vital capacity, forced expiratory volume in the first second of exhalation, and peak cough flow measures
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Anti-adeno-associated virus type 8 neutralizing activity
Number of subjects: 45
Study: 30902915

Group type: EXPERIMENTAL
Intervention: Atezolizumab (PD-L1 inhibition) with paclitaxel and carboplatin, radiotherapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Paclitaxel (chemotherapy)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Atezolizumab (PD-L1 inhibition)
Number of subjects: 2
Study: 30903140

Group type: EXPERIMENTAL
Intervention: Neoadjuvant lapatinib plus trastuzumab
Number of subjects: 56

Group type: COMPARATOR
Intervention: HER2 ratio <4 and/or CN <10
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: HER2 ratio ≥4 and/or CN ≥10
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High PTEN or wild-type PIK3CA (intact PI3K pathway)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: HER2 ratio ≥4 and intact PI3K pathway
Number of subjects: 56
Study: 30903175

Group type: EXPERIMENTAL
Intervention: Simultaneous hybrid coronary revascularization (sHCR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CABG)
Number of subjects: 50
Study: 30903184

Group type: EXPERIMENTAL
Intervention: Maternal OSA
Number of subjects: 53
Study: 30903275

Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg orally QD)
Number of subjects: 20
Study: 30903647

Group type: EXPERIMENTAL
Intervention: IMPROD biparametric prostate MRI (bpMRI)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: IMPROD bpMRI with 3D dilation of manual cancer delineations
Number of subjects: 64
Study: 30903661

Group type: EXPERIMENTAL
Intervention: Plans to keep pills
Number of subjects: 217

Group type: COMPARATOR
Intervention: Plans to dispose of pills
Number of subjects: 217
Study: 30904017

Group type: EXPERIMENTAL
Intervention: Pregnancy-related food taboos (PRFT) adherence among anemic women (n=187)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Pregnancy-related food taboos (PRFT) adherence among non-anemic women (n=405)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Association of PRFT with anemia
Number of subjects: 592
Study: 30904021

Group type: EXPERIMENTAL
Intervention: myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day), glucomannan (4 g/day) for 3 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: myo-inositol, D-chiro-inositol, glucomannan
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 30904064

Group type: EXPERIMENTAL
Intervention: Spironolactone up to 25 mg/d
Number of subjects: 0
Study: 30904228

Group type: EXPERIMENTAL
Intervention: In-person classes focusing on a plant-based diet rich in anti-inflammatory foods, duration: 12 months.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group receiving newsletters, duration: 12 months.
Number of subjects: 95
Study: 30904580

Group type: EXPERIMENTAL
Intervention: Exposure to Alternaria fungal spores in the classroom
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (sensitized but not exposed to Alternaria)
Number of subjects: 280
Study: 30904742

Group type: EXPERIMENTAL
Intervention: Increased plasma level of Lp-PLA2
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Lp-PLA2
Number of subjects: 1452
Study: 30904743

Group type: EXPERIMENTAL
Intervention: Second-line glucose-lowering therapy
Number of subjects: 15992
Study: 30904830

Group type: EXPERIMENTAL
Intervention: Methotrexate administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Number of subjects: 0
Study: 30904854

Group type: EXPERIMENTAL
Intervention: Internet-based, therapist-guided cognitive-behavioural therapy (CBT) for BDD, 12-week treatment consisting of eight treatment modules.
Number of subjects: 32
Study: 30904859

Group type: EXPERIMENTAL
Intervention: Low-dose chest CT lung cancer screening
Number of subjects: 0
Study: 30904869

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) at dose levels of 6Gy×5F, 7Gy×5F, 8Gy×5F followed by four cycles of modified FOLFOX6 (mFOLFOX6) chemotherapy as neoadjuvant therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-course radiotherapy (SCRT) (25 Gy over five fractions) followed immediately by surgery.
Number of subjects: 0
Study: 30904980

Group type: EXPERIMENTAL
Intervention: Pralatrexate IV 30 mg/m²
Number of subjects: 71
Study: 30905354

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) every 3 months until complete remission (CR)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: RFA for treatment of flat USLs
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Pink-color sign at baseline
Number of subjects: 78
Study: 30905623

Group type: EXPERIMENTAL
Intervention: Later bedtime
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Nocturnal sleep time
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Sleep time and later bedtime
Number of subjects: 87
Study: 30906106

Group type: EXPERIMENTAL
Intervention: Fractional Brownian motion combined with moving linear regression
Number of subjects: 42418

Group type: COMPARATOR
Intervention: Classic Brownian motion
Number of subjects: 42418
Study: 30906291

Group type: EXPERIMENTAL
Intervention: Booster vaccination with GVGH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30906596

Group type: EXPERIMENTAL
Intervention: 12-week resistance exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal weight participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 0
Study: 30906694

Group type: COMPARATOR
Intervention: Gambling intervention only (G only)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Gambling intervention with mental health intervention (G + MH)
Number of subjects: 214
Study: 30906874

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 488
Study: 30907259

Group type: EXPERIMENTAL
Intervention: EndoAnchor implants with good penetration
Number of subjects: 54
Study: 30907261

Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale-Extended (GOSE)
Number of subjects: 0
Study: 30907453

Group type: EXPERIMENTAL
Intervention: Anti-staphylococcal treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 30907508

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) kits distributed
Number of subjects: 175683
Study: 30907744

Group type: EXPERIMENTAL
Intervention: Values-affirmation writing exercise
Number of subjects: 1130

Group type: COMPARATOR
Intervention: Control writing exercise
Number of subjects: 1130
Study: 30907811

Group type: EXPERIMENTAL
Intervention: Free abdominal flaps
Number of subjects: 30
Study: 30907859

Group type: EXPERIMENTAL
Intervention: Simultaneous-image contact lenses (prototype and commercially available)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Overall vision satisfaction ratings
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Vision stability ratings (daytime)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Other subjective ratings
Number of subjects: 141
Study: 30908579

Group type: EXPERIMENTAL
Intervention: Allodynography
Number of subjects: 12
Study: 30908927

Group type: EXPERIMENTAL
Intervention: Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exacerbations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 0
Study: 30909729

Group type: EXPERIMENTAL
Intervention: Higher stressful life events (highest versus lowest quartile) at age 55
Number of subjects: 10785

Group type: EXPERIMENTAL
Intervention: Higher stressful life events (highest versus lowest quartile) at age 65
Number of subjects: 10785

Group type: EXPERIMENTAL
Intervention: Higher stressful life events in multivariable-adjusted models (sub-cohort with updated measures)
Number of subjects: 10785

Group type: EXPERIMENTAL
Intervention: Social strain
Number of subjects: 10785

Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 10785
Study: 30909832

Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg
Number of subjects: 8
Study: 30909922

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 333
Study: 30910003

Group type: EXPERIMENTAL
Intervention: Perioperative indwelling urinary catheterisation
Number of subjects: 795
Study: 30910221

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone treatment (mean dose: 0.4mg/kg/week at month 0, M12, M24; 0.3mg/kg/week at M36)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone treatment
Number of subjects: 98
Study: 30910346

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200mg every 3 weeks until progression or unacceptable toxicity
Number of subjects: 1004
Study: 30910709

Group type: EXPERIMENTAL
Intervention: PARAD+ discrimination algorithm
Number of subjects: 1013
Study: 30910890

Group type: EXPERIMENTAL
Intervention: Weight-based dosing guidelines for antituberculosis drugs
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Dose increment of one fixed-dose combination (FDC) tablet for weight bands of 30 to 37 and 38 to 54 kg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Concomitant use of efavirenz
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Different formulations of rifampin and isoniazid
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Current dosing guidelines
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Adding one FDC tablet to current weight band-based dosing
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Lower isoniazid exposures due to efavirenz
Number of subjects: 268
Study: 30910891

Group type: EXPERIMENTAL
Intervention: Intravenous rifampin, 8 mg/kg for <14 days PNA, 15 mg/kg for ≥14 days PNA, administered once daily
Number of subjects: 27
Study: 30910892

Group type: EXPERIMENTAL
Intervention: Intravenous and oral fluconazole
Number of subjects: 75
Study: 30911064

Group type: EXPERIMENTAL
Intervention: Prenatal acetaminophen use (any use)
Number of subjects: 2291

Group type: COMPARATOR
Intervention: No prenatal acetaminophen use
Number of subjects: 2291
Study: 30911405

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) administered by EMS paramedics using the autoRIC® device, 4 cycles of 5-min inflation and 5-min deflation of an upper arm cuff
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Qualitative data collection from study participants and paramedics regarding study procedures
Number of subjects: 50
Study: 30911655

Group type: EXPERIMENTAL
Intervention: Adjuvant PIPAC-directed therapy with oxaliplatin (92 mg/m2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adjuvant PIPAC-directed therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PIPAC-directed therapy
Number of subjects: 60
Study: 30911657

Group type: EXPERIMENTAL
Intervention: ABP (Abraxane™) administered via pressurized intraperitoneal aerosol chemotherapy (PIPAC) at escalating doses from 35 to 140 mg/m², with three treatments at 4-week intervals.
Number of subjects: 0
Study: 30911656

Group type: EXPERIMENTAL
Intervention: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using doxorubicin (1.5 mg/m²) in series of three procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI as a staging and response evaluation tool
Number of subjects: 0
Study: 30911663

Group type: EXPERIMENTAL
Intervention: PIPAC with oxaliplatin (starting dose 45 mg/m)
Number of subjects: 0
Study: 30911664

Group type: EXPERIMENTAL
Intervention: Oxaliplatin administered by the intraperitoneal route (PIPAC) at a starting dose of 90 mg/m², during two consecutive procedures at a 4-6 week interval.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin via PIPAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose oxaliplatin during PIPAC
Number of subjects: 0
Study: 30911669

Group type: EXPERIMENTAL
Intervention: PIPAC C/D (cisplatin and doxorubicin)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: PIPAC OX (oxaliplatin)
Number of subjects: 41

Group type: COMPARATOR
Intervention: PIPAC OX
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: PIPAC procedure
Number of subjects: 41
Study: 30911859

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + chemotherapy (200 mg on day 1, cisplatin 80 mg/m)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pembrolizumab (monotherapy)
Number of subjects: 56
Study: 30911926

Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin (EPFX) 200 mg twice daily (days 1-5); once daily on alternate days (days 7-25)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Vancomycin 125 mg four times daily (days 1-10)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin (EPFX)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 356
Study: 30912033

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 65
Study: 30912699

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 128
Study: 30912761

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief exercise counseling combined with HIIT or MICT
Number of subjects: 0
Study: 30912762

Group type: EXPERIMENTAL
Intervention: My JAKE app
Number of subjects: 144
Study: 30913032

Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SAT) distribution measurements at 15 standardized locations
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Nuchal and hip SAT thickness measurements
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Correlation analysis of RTL with body fat parameters
Number of subjects: 375
Study: 30913226

Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension 12 mg/kg/day BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension 18 mg/kg/day TID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension 18 mg/kg/day BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension 12 mg/kg/day BID, 18 mg/kg/day BID, and 18 mg/kg/day TID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension
Number of subjects: 0
Study: 30914274

Group type: EXPERIMENTAL
Intervention: FSH treatment (3-6 hours)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Elevated FSH (>11 U/L) in infertile men
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Men with prediabetes
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: FSH levels
Number of subjects: 335
Study: 30914909

Group type: EXPERIMENTAL
Intervention: XNKQ acupuncture (manual needle-stimulation on five acupuncture points: DU26 unilaterally, PC6, and SP6 bilaterally)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Needle-stimulation on non-acupuncture points (manual needle-stimulation on five nearby non-acupuncture points)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Insertion of needles on the XNKQ acupuncture points without stimulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Insertion of needles on the non-acupuncture points without stimulation
Number of subjects: 24